Näytetään 1 - 20 yhteensä 31 tuloksesta haulle 'Alwin D.R. Huitema', hakuaika: 0,06s
Tarkenna hakua
-
1
Editorial: Therapeutic Drug Monitoring (TDM): A Useful Tool for Pediatric Pharmacology Applied to Routine Clinical Practice Tekijä Raffaele Simeoli, Thomas P. C. Dorlo, Lidwien M. Hanff, Alwin D. R. Huitema, Alwin D. R. Huitema, Alwin D. R. Huitema, Erwin Dreesen
Julkaistu 2022-05-01
Artikkeli -
2
A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer Drugs Tekijä Laura Molenaar-Kuijsten, Dorieke E. M. Van Balen, Jos H. Beijnen, Jos H. Beijnen, Neeltje Steeghs, Alwin D. R. Huitema, Alwin D. R. Huitema, Alwin D. R. Huitema
Julkaistu 2021-08-01
Artikkeli -
3
Harnessing soft tissue sarcoma with low-dose pazopanib – a matter of blood levels Tekijä Stefanie L. Groenland, Daniela Katz, Alwin D. R. Huitema, Neeltje Steeghs
Julkaistu 2018-12-01
Artikkeli -
4
Predictability of human exposure by human‐CYP3A4‐transgenic mouse models: A meta‐analysis Tekijä David Damoiseaux, Alfred H. Schinkel, Jos H. Beijnen, Alwin D. R. Huitema, Thomas P. C. Dorlo
Julkaistu 2024-01-01
Artikkeli -
5
-
6
-
7
-
8
-
9
Quantification of neutralizing anti-drug antibodies and their neutralizing capacity using competitive displacement and tandem mass spectrometry: Infliximab as proof of principle Tekijä Mohsin El Amrani, Camiel Göbel, Annelies C. Egas, Stefan Nierkens, C. Erik Hack, Alwin D.R. Huitema, Erik M. van Maarseveen
Julkaistu 2019-04-01
Artikkeli -
10
Predictiveness of the Human-CYP3A4-Transgenic Mouse Model (Cyp3aXAV) for Human Drug Exposure of CYP3A4-Metabolized Drugs Tekijä David Damoiseaux, Wenlong Li, Alejandra Martínez-Chávez, Jos H. Beijnen, Alfred H. Schinkel, Alwin D. R. Huitema, Thomas P. C. Dorlo
Julkaistu 2022-07-01
Artikkeli -
11
Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, mul... Tekijä Marinda Meertens, M. Benthe Muntinghe-Wagenaar, Barend J. Sikkema, Marta Lopez-Yurda, Valesca P. Retèl, Marthe S. Paats, Rob Ter Heine, Ed Schuuring, Wim Timens, Daan J. Touw, Job F. M. van Boven, Adrianus. J. de Langen, Sayed M. S. Hashemi, Lizza E. L. Hendriks, Sander Croes, Michel M. van den Heuvel, Anne-Marie C. Dingemans, Ron H. J. Mathijssen, Egbert F. Smit, Alwin D. R. Huitema, Alwin D. R. Huitema, Alwin D. R. Huitema, Neeltje Steeghs, Anthonie J. van der Wekken
Julkaistu 2023-03-01
Artikkeli -
12
A physiologically based pharmacokinetic model for [68Ga]Ga-(HA-)DOTATATE to predict whole-body distribution and tumor sink effects in GEP-NET patients Tekijä Hinke Siebinga, Berlinda J. de Wit-van der Veen, Jos H. Beijnen, Thomas P. C. Dorlo, Alwin D. R. Huitema, Jeroen J. M. A. Hendrikx
Julkaistu 2023-02-01
Artikkeli -
13
Adherence to low-dose methotrexate in children with juvenile idiopathic arthritis using a sensitive methotrexate assay Tekijä Julia E. Möhlmann, Sytze de Roock, Annelies C. Egas, Evelien ter Weijden, Martijn J. H. Doeleman, Alwin D. R. Huitema, Matthijs van Luin, Joost F. Swart
Julkaistu 2024-05-01
Artikkeli -
14
Clinical Trial Simulation To Optimize Trial Design for Fludarabine Dosing Strategies in Allogeneic Hematopoietic Cell Transplantation Tekijä Jurgen B. Langenhorst, Thomas P.C. Dorlo, Charlotte vanKesteren, Erik M. vanMaarseveen, Stefan Nierkens, Moniek A. deWitte, Jaap Jan Boelens, Alwin D.R. Huitema
Julkaistu 2020-05-01
Artikkeli -
15
Quantification of biochemical PSA dynamics after radioligand therapy with [177Lu]Lu-PSMA-I&T using a population pharmacokinetic/pharmacodynamic model Tekijä Hinke Siebinga, Berlinda J. de Wit-van der Veen, Daphne M. V. de Vries-Huizing, Wouter V. Vogel, Jeroen J. M. A. Hendrikx, Alwin D. R. Huitema
Julkaistu 2024-04-01
Artikkeli -
16
Optimization of a Quantitative Anti-Drug Antibodies against Infliximab Assay with the Liquid Chromatography-Tandem Mass Spectrometry: A Method Validation Study and Future Perspecti... Tekijä Erin H. Smeijsters, Kim C. M. van der Elst, Amy Visch, Camiel Göbel, Floris C. Loeff, Theo Rispens, Alwin D. R. Huitema, Matthijs van Luin, Mohsin El Amrani
Julkaistu 2023-05-01
Artikkeli -
17
PropAngio study protocol: a neoadjuvant trial on the efficacy of propranolol monotherapy in cutaneous angiosarcoma—a proof of principle study Tekijä Neeltje Steeghs, Jos H Beijnen, Kimberley M Heinhuis, Nikki S IJzerman, Anne Miek Koenen, Winette T A van der Graaf, Rick L Haas, Alwin D R Huitema, Winan J van Houdt
Julkaistu 2020-09-01
Artikkeli -
18
Predicting [177Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [68Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling Tekijä Hinke Siebinga, Berlinda J. de Wit-van der Veen, Jos H. Beijnen, Marcel P. M. Stokkel, Thomas P. C. Dorlo, Alwin D. R. Huitema, Jeroen J. M. A. Hendrikx
Julkaistu 2023-08-01
Artikkeli -
19
Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis Tekijä Bart A.W. Jacobs, Maarten J. Deenen, Markus Joerger, Hilde Rosing, Niels deVries, Didier Meulendijks, Annemieke Cats, Jos H. Beijnen, Jan H.M. Schellens, Alwin D.R. Huitema
Julkaistu 2019-12-01
Artikkeli -
20
Neutropenia and docetaxel exposure in metastatic castration‐resistant prostate cancer patients: A meta‐analysis and evaluation of a clinical cohort Tekijä Aurelia H. M. deVries Schultink, Marie‐Rose B. S. Crombag, Erik vanWerkhoven, Hans‐Martin Otten, Andre M. Bergman, Jan H. M. Schellens, Alwin D. R. Huitema, Jos H. Beijnen
Julkaistu 2019-04-01
Artikkeli